<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038515</url>
  </required_header>
  <id_info>
    <org_study_id>2000025408</org_study_id>
    <nct_id>NCT04038515</nct_id>
  </id_info>
  <brief_title>Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes</brief_title>
  <official_title>Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this application is to test whether menthol and fruit flavors impact e-cigarette
      use through dissociable mechanisms and exert their effects differentially across nicotine
      doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study examines the impact of menthol and fruit flavors on self-administration of
      e-cigarette solutions containing varying amounts of nicotine. This is a randomized,
      double-blind study with a within-subject cross-over design, using e-liquids with 5 different
      flavors and 4 different levels of nicotine for a total of 20 different e-liquid formulations.
      Each subject will participate in 4 test sessions. The order of flavor and nicotine delivery
      will be randomized. At each test session, they will undergo directed self-administration, in
      a randomized order, then an ad libitum self-administration session where they can choose
      among all of the e-cigarettes used during the directed session. The primary aims assess the
      impacts of nicotine and flavor (and their interactions) on participants' subjective ratings
      of the e-liquids during the 'directed' self-administration component, and self-administered
      puffs during the ad libitum self-administration component. In addition, the study will
      explore the impact of sex/gender and sensitivity to nicotine aversiveness or bitterness (as
      operationalized by genetic variations in the alpha-5 subunit of nicotinic acetylcholine
      receptor that influences the aversive effects of nicotine, or a taste receptor number 38 (
      TAS2R38) important for bitterness perception) on study outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 15, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a within-subject, cross-over design. Participants will be invited to complete 4 test sessions. Across those 4 test sessions, participants will self-administer e-cigarettes containing all 20 e-liquid conditions (4 nicotine * 5 flavor conditions) in both 'directed' and ad libitum self-administration study components. The order of nicotine and flavor will be randomized across participants.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a double-blind study. Although participants will receive all conditions in this within-subject cross-over study, the participant and researcher will be blinded to the order of e-liquid conditions (nicotine level, flavor) across and within test sessions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Subjective drug ratings</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Subjective ratings of e-liquids delivered via e-cigarette will be assessed during the 'directed' self-administration component of each test day, using visual analogue scales (VAS). VAS scores range from 0=not at all to 100=extremely. Separate VAS scales will be collected for subjective ratings of aversive properties (higher scores reflect more aversiveness) and rewarding properties (higher scores reflect more rewarding properties) of the e-cigarettes, in each nicotine*flavor condition. Subjective drug ratings for each nicotine*flavor condition will be tested at one test day only and the order of nicotine*flavor conditions will be randomized across the test days (and order within test days will be randomized).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>E-cigarette use</measure>
    <time_frame>immediately after intervention</time_frame>
    <description>Number of puffs from each e-cigarette (containing different e-liquids) will be measured during the ad libitum self-administration component of each test day. E-cigarette use (ad libitum puffs) for each nicotine*flavor condition will be tested at one test day only and the order of nicotine*flavor conditions will be randomized across the test days (and order within test days will be randomized).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Nicotine</condition>
  <condition>Vaping</condition>
  <arm_group>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order 'A' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order 'B' for E-liquid Self-Administration: All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One nicotine level condition is a medium nicotine e-liquid (12 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One nicotine level condition is a high nicotine e-liquid (24 mg/mL nicotine). All participants will be given all e-liquids (i.e., all 20 nicotine*flavor combinations (4 nicotine* 5 flavor combinations)) in this within-subject, cross-over design study. Participants will be randomized the order in which they self-administer the 20 nicotine*flavor combinations of e-liquid (across and within the 4 visits). The specific order cannot be described here without disrupting the double-blind nature of the study design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine 0 mg/mL</intervention_name>
    <description>E-liquid containing no nicotine (0 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).</description>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <other_name>nicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine 6 mg/mL</intervention_name>
    <description>E-liquid containing low nicotine (6 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).</description>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <other_name>nicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine 12 mg/mL</intervention_name>
    <description>E-liquid containing medium nicotine ( 12 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).</description>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <other_name>nicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine 24 mg/mL</intervention_name>
    <description>E-liquid containing high nicotine ( 24 mg/mL nicotine) will be self-administered via e-cigarettes. This will be administered in 5 flavor conditions (1 unflavored, 2 menthol, and 2 fruit conditions).</description>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <other_name>nicotine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>'Menthol' flavor</intervention_name>
    <description>E-liquid containing 'menthol' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).</description>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <other_name>menthol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>'Menthol/Mint' flavor</intervention_name>
    <description>E-liquid containing 'menthol/mint' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).</description>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <other_name>menthol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>'Green Apple' flavor</intervention_name>
    <description>E-liquid containing 'green apple' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).</description>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <other_name>fruit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>'Watermelon' flavor</intervention_name>
    <description>E-liquid containing 'watermelon' flavor will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).</description>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <other_name>fruit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>'Unflavored'</intervention_name>
    <description>E-liquid containing no additional flavor (i.e., 'unflavored') will be self-administered via e-cigarettes. This will be administered in 4 nicotine conditions (0, 6, 12, 24 mg/mL nicotine).</description>
    <arm_group_label>E-liquid Order 'A'</arm_group_label>
    <arm_group_label>E-liquid Order 'B'</arm_group_label>
    <arm_group_label>E-liquid Order 'C'</arm_group_label>
    <arm_group_label>E-liquid Order 'D'</arm_group_label>
    <other_name>unflavored</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Past month daily cigarette, nicotine-containing e-cigarette, and/or cigar/little
             cigar/cigarillo use.

          -  Urine cotinine levels consistent with regular nicotine use

          -  For women, using acceptable birth control methods

          -  Able to read and write English

        Exclusion Criteria:

          -  Current or history of major medical illness psychiatric diagnosis or substance use or
             psychotropic medication use that the physician investigator deems a contraindication
             for study participation

          -  Current psychiatric diagnosis of bipolar affective disorder, schizophrenia, homicidal
             or suicidal ideation

          -  Any allergy to propylene glycol, vegetable glycerin, menthol, mint, green apple or
             watermelon flavorants

          -  For women, pregnant as determined by pregnancy screening, or breast feeding

          -  Seeking (or undergoing) treatment for nicotine dependence or smoking

          -  Inability/unwillingness to fulfill scheduled visits and procedures including directed
             self-administration of all e-liquid flavors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elise DeVito, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elise DeVito, PhD</last_name>
    <phone>203-737-4882</phone>
    <email>elise.devito@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Elise DeVito, PhD</last_name>
      <phone>203-737-4882</phone>
      <email>elise.devito@yale.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2019</study_first_posted>
  <last_update_submitted>May 5, 2020</last_update_submitted>
  <last_update_submitted_qc>May 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Menthol</keyword>
  <keyword>Electronic Nicotine Delivery Systems</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

